De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results - Harbeck, N; Gluz, O; Christgen, M (J Clin Oncol, 2021)